Galectin Therapeutics
GALT
78 hedge funds and large institutions have $23.9M invested in Galectin Therapeutics in 2020 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 22 increasing their positions, 18 reducing their positions, and 3 closing their positions.
267% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 3
22% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 18
18% more call options, than puts
Call options by funds: $436K | Put options by funds: $368K
10% more funds holding
Funds holding: 71 → 78 (+7)
1.21% more ownership
Funds ownership: 17.65% → 18.87% (+1.2%)
11% less capital invested
Capital invested by funds: $26.9M → $23.9M (-$2.96M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GWM
Geneos Wealth Management
Englewood,
Colorado
|
+$1.18M |
| 2 |
BlackRock
New York
|
+$249K |
| 3 |
JP Morgan Chase
New York
|
+$215K |
| 4 |
OSAM
O'Shaughnessy Asset Management
Stamford,
Connecticut
|
+$190K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
+$158K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DADC
D.A. Davidson & Co
Great Falls,
Montana
|
-$227K |
| 2 |
Two Sigma Investments
New York
|
-$161K |
| 3 |
Neuberger Berman Group
New York
|
-$146K |
| 4 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$74K |
| 5 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
-$72K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AIG
76
American International Group
New York
| $48 | -$1.63K | -622 | -3% |
|
|
RJA
77
Raymond James & Associates
St Petersburg,
Florida
| – | -$74K | -27,740 | Closed |
|
|
78
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| – | -$72K | -26,819 | Closed |
|
79
Two Sigma Advisers
New York
| – | -$42K | -15,900 | Closed |
|
80
Simplex Trading
Chicago,
Illinois
| – | +$155 | +59 | New |
|
GALT Hedge Fund Activity: Q4 2020 in Review
78 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q4 2020, worth a combined $23.9M — down 11% from $26.9M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new GALT positions and 3 closed out — a net gain of 8 holders — while 22 added to existing stakes and 18 trimmed.
The largest buyer was Geneos Wealth Management, adding an estimated $1.18M. The largest seller was D.A. Davidson & Co, cutting an estimated $227K.
- 78 institutional investors held Galectin Therapeutics (GALT) as of Q4 2020, up from 71 in Q3 2020.
- Funds reported $23.9M of Galectin Therapeutics stock for Q4 2020, down 11% quarter-over-quarter.
- 11 funds opened new Galectin Therapeutics positions in Q4 2020 and 3 closed out, a net change of +8 holders.
- The largest Galectin Therapeutics buyer in Q4 2020 was Geneos Wealth Management, an estimated $1.18M added.
- The largest Galectin Therapeutics seller in Q4 2020 was D.A. Davidson & Co, an estimated $227K sold.
Based on aggregated 13F filings for Q4 2020.